Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Jorg Dietrich, M.D.,Ph.D.


This page shows the publications co-authored by Jorg Dietrich and Helen Shih.
Connection Strength

  1. Clinical Presentation and Management of SMART Syndrome. Neurology. 2021 May 04.
    View in: PubMed
    Score: 0.227
  2. Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. Oncologist. 2020 08; 25(8):e1221-e1232.
    View in: PubMed
    Score: 0.213
  3. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Med. 2020 01; 9(1):3-11.
    View in: PubMed
    Score: 0.204
  4. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
    View in: PubMed
    Score: 0.192
  5. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68.
    View in: PubMed
    Score: 0.173
  6. Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. Neurology. 2017 Feb 21; 88(8):789-796.
    View in: PubMed
    Score: 0.169
  7. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 03 14; 13(1):1325.
    View in: PubMed
    Score: 0.060
  8. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
    View in: PubMed
    Score: 0.058
  9. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.054
  10. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.